NASDAQ: RVNCRevance Therapeutics Inc Stock
$3.61-0.08 (-2.17%)
Updated Apr 30, 2024
RVNC Price
$3.61
Fair Value Price
N/A
Market Cap
$318.45M
52 Week Low
$3.21
52 Week High
$37.98
P/E
-0.94x
P/B
-2.1x
P/S
3.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$234.04M
Earnings
-$323.99M
Gross Margin
68.2%
Operating Margin
-130.03%
Profit Margin
-138.4%
Debt to Equity
-4.16
Operating Cash Flow
-$217M
Beta
1.27
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RVNC Overview
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RVNC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVNC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RVNC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RVNC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RVNC due diligence checks available for Premium users.
Be the first to know about important RVNC news, forecast changes, insider trades & much more!
RVNC News
Valuation
RVNC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
14.91x
Market
40.82x
RVNC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.1x
Industry
5.89x
RVNC's financial health
Profit margin
Revenue
$69.8M
Net Income
-$55.7M
Profit Margin
-79.8%
RVNC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RVNC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$478.5M
Liabilities
$630.1M
Debt to equity
-4.16
RVNC's short-term assets ($338.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RVNC's long-term liabilities ($540.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RVNC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RVNC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$42.7M
Investing
$2.4M
Financing
-$1.6M
RVNC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RVNC vs Biotech Stocks
Revance Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.